Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243257 | 0.82 | ALDH1A1 (0.43) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL6239062 | 0.78 | KDM4E (0.50) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL6243775 | 0.69 | KDM4E (0.43) | KDM4EMAPTLMNAPOLBPKM | |
| SCHEMBL6241087 | 0.67 | ALDH1A1 (0.45) | KDM4EMAPTLMNAALDH1A1THRB | |
| SCHEMBL4003903 | 0.67 | KDM4E (0.50) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL6240166 | 0.63 | LMNA (0.51) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL7434650 | 0.59 | ALDH1A1 (0.54) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL6240374 | 0.59 | MAPT (0.46) | KDM4EMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL4003191 | 0.58 | DRD4 (0.70) | KDM4EPOLBALDH1A1KMT2A | |
| SCHEMBL4009678 | 0.57 | RAB9A (0.52) | KDM4EMAPTLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KDM4E 2903/4885MAPT 3896/4885LMNA 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.